The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•10 March 2026•

1 min read

C4 Therapeutics Reports 111% Revenue Growth and Advances Cemsidomide to Phase 2

Key Facts

1C4 Therapeutics revenue grew by 111.5% YoY in the fourth quarter of 2025.

2The company's lead asset, cemsidomide, advanced into a Phase 2 registrational trial for multiple myeloma.

C4 Therapeutics (CCCC) announced robust financial results for the fourth quarter of 2025, highlighted by a 111.5% year-over-year revenue increase. The biotechnology firm achieved a significant clinical milestone as its lead drug candidate, cemsidomide, transitioned into a Phase 2 registrational trial for treating multiple myeloma. This advancement underscores the company's progress in its oncology pipeline and its focus on targeted protein degradation therapies. Financially, the company remains in a strong position with a cash balance of $297.1 million as of the end of the quarter. Management noted that this liquidity provides a stable operational runway extending into 2028, supporting ongoing research and development. The combination of clinical success and disciplined financial management has bolstered investor confidence in the company's long-term growth prospects.